BR0208900A - Indolinas substituìdas na posição 6 e seu uso como inibidores de cinase - Google Patents

Indolinas substituìdas na posição 6 e seu uso como inibidores de cinase

Info

Publication number
BR0208900A
BR0208900A BR0208900-9A BR0208900A BR0208900A BR 0208900 A BR0208900 A BR 0208900A BR 0208900 A BR0208900 A BR 0208900A BR 0208900 A BR0208900 A BR 0208900A
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
indolines
salts
substituted indolines
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0208900-9A
Other languages
English (en)
Inventor
Frank Hilberg
Armin Heckel
Thorsten Lehmann-Lintz
Gerald Juergen Roth
Joerg Kley
Jacobus Van Meel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of BR0208900A publication Critical patent/BR0208900A/pt
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"INDOLINAS SUBSTITUìDAS NA POSIçãO 6 E SEU USO COMO INIBIDORES DE CINASE". A invenção refere-se a indolinas substituídas na posição 6, da fórmula geral (I), na qual R~ 5~ até R~ 5~ e X são tal como definidos na reivindicação 1, a seus isómeros e seus sais, particularmente seus sais fisiologicamente compatíveis, os quais apresentam valiosas propriedades farmacológicas, particularmente uma ação inibidora sobre diferentes cinases de receptores tirosina e complexos ciclina/CDK bem como sobre a proliferação de células endoteliais e diferentes células de tumores, medicamentos contendo estes compostos, seu uso e processo para sua preparação.
BR0208900-9A 2001-04-06 2002-03-30 Indolinas substituìdas na posição 6 e seu uso como inibidores de cinase Pending BR0208900A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10117204A DE10117204A1 (de) 2001-04-06 2001-04-06 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2002/003583 WO2002081445A1 (de) 2001-04-06 2002-03-30 In 6-stellung substituierte indoline und ihre verwendung als kinase-inhibitoren

Publications (1)

Publication Number Publication Date
BR0208900A true BR0208900A (pt) 2004-04-20

Family

ID=7680648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208900-9A Pending BR0208900A (pt) 2001-04-06 2002-03-30 Indolinas substituìdas na posição 6 e seu uso como inibidores de cinase

Country Status (23)

Country Link
US (1) US6858641B2 (pt)
EP (1) EP1379501A1 (pt)
JP (1) JP2004525173A (pt)
KR (1) KR20030090712A (pt)
CN (1) CN1509270A (pt)
AR (1) AR035813A1 (pt)
BG (1) BG108220A (pt)
BR (1) BR0208900A (pt)
CA (1) CA2442695A1 (pt)
CZ (1) CZ20032975A3 (pt)
DE (1) DE10117204A1 (pt)
EA (1) EA200301005A1 (pt)
EC (1) ECSP034776A (pt)
EE (1) EE200300491A (pt)
HU (1) HUP0303737A3 (pt)
IL (1) IL158254A0 (pt)
MX (1) MXPA03008896A (pt)
NO (1) NO20034434D0 (pt)
PE (1) PE20021058A1 (pt)
PL (1) PL366458A1 (pt)
SK (1) SK12412003A3 (pt)
WO (1) WO2002081445A1 (pt)
ZA (1) ZA200307306B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20060154939A1 (en) * 2004-12-24 2006-07-13 Boehringer Ingelheim International Gmbh Medicaments for the Treatment or Prevention of Fibrotic Diseases
PE20061155A1 (es) * 2004-12-24 2006-12-16 Boehringer Ingelheim Int Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
JP5681855B2 (ja) 2007-10-12 2015-03-11 アストラゼネカ エービー プロテインキナーゼの阻害剤
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US8344018B2 (en) * 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
AU2009275964A1 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh New compounds
US8518948B2 (en) 2010-03-10 2013-08-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
CN102267934B (zh) * 2010-06-02 2013-04-17 金凯美(大连)医药科技有限公司 一种6-甲氧羰基吲哚酮的制备方法
US11046672B2 (en) * 2015-12-24 2021-06-29 Respivert Limited Indolinones compounds and their use in the treatment of fibrotic diseases
EA038773B1 (ru) 2016-03-08 2021-10-18 Респиверт Лимитед Индольные производные и их применение в качестве ингибиторов протеинкиназы

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1247803A3 (en) * 1996-08-23 2002-10-16 Sugen, Inc. Indolinone compounds suitable for modulation of protein kinases
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6043254A (en) 1998-04-03 2000-03-28 Boehringer Ingelheim Pharma Kg Indolinones having kinase-inhibiting activity
DE19816624A1 (de) 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6169106B1 (en) 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
US6319918B1 (en) * 1998-06-04 2001-11-20 Boehringer Ingelheim Pharma Kg Substituted indolinones with kinase inhibitory activity
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19940829A1 (de) 1999-08-27 2001-03-01 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE316527T1 (de) 1999-08-27 2006-02-15 Boehringer Ingelheim Pharma Substituierte indolinone als tyrosinkinase inhibitoren
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10042696A1 (de) 2000-08-31 2002-03-14 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2442695A1 (en) 2002-10-17
DE10117204A1 (de) 2002-10-10
HUP0303737A2 (hu) 2004-03-01
US20030092756A1 (en) 2003-05-15
AR035813A1 (es) 2004-07-14
PE20021058A1 (es) 2003-01-20
IL158254A0 (en) 2004-05-12
EP1379501A1 (de) 2004-01-14
NO20034434L (no) 2003-10-03
EA200301005A1 (ru) 2004-04-29
CN1509270A (zh) 2004-06-30
ZA200307306B (en) 2004-08-31
CZ20032975A3 (cs) 2004-02-18
KR20030090712A (ko) 2003-11-28
US6858641B2 (en) 2005-02-22
ECSP034776A (es) 2003-12-01
JP2004525173A (ja) 2004-08-19
HUP0303737A3 (en) 2004-09-28
PL366458A1 (en) 2005-02-07
BG108220A (bg) 2004-09-30
WO2002081445A1 (de) 2002-10-17
EE200300491A (et) 2004-02-16
NO20034434D0 (no) 2003-10-03
MXPA03008896A (es) 2003-12-08
SK12412003A3 (sk) 2004-04-06

Similar Documents

Publication Publication Date Title
BRPI0014735A (pt) composto 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metóxicarbonil-2-indolinona, seus sais e seu uso, bem como composição farmacêutica e seu processo de preparação.
BR9909688A (pt) Indolinonas substituìdas, a sua preparação e seu uso como composições farmacêuticas
BR0208900A (pt) Indolinas substituìdas na posição 6 e seu uso como inibidores de cinase
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
CY1106933T1 (el) Ενωσεις πυριμιδινης
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BRPI0117360B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BRPI0116266B8 (pt) "derivado de quinazolina e seu uso, bem como composição farmacêutica".
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
MEP13408A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
BR0308902A (pt) 4-(n-fenilamino)-quinazolinas/quinolinas como inibidoras da tirosina cinase
BRPI0510770A (pt) derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
BR0312648A (pt) Processo para preparação de certos compostos pirrolo triazina
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
BR0315988A (pt) Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos
BRPI0414489A8 (pt) derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BRPI0508364A (pt) derivados de 4-benzimidazol-2-ilpiridazin-3-ona
BRPI0507375A (pt) derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase
BR0108605A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d]tiazol, que na posição 8a são substituìdos; processos para a sua preparação e seu emprego como medicamentos, por exemplo, como anoréxicos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]